Juno Therapeutics, Inc. (JUNO) Trading 7.5% Higher
Juno Therapeutics, Inc. (NASDAQ:JUNO) traded up 7.5% during mid-day trading on Wednesday . The stock traded as high as $45.75 and last traded at $45.32. 4,448,379 shares were traded during trading, an increase of 79% from the average session volume of 2,490,520 shares. The stock had previously closed at $42.15.
JUNO has been the topic of a number of recent research reports. Vetr raised shares of Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 target price on the stock in a research report on Monday, August 14th. Zacks Investment Research cut shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Morgan Stanley boosted their target price on shares of Juno Therapeutics from $26.00 to $27.00 and gave the stock an “equal weight” rating in a research report on Monday, August 7th. Wedbush reissued a “neutral” rating and set a $24.00 target price on shares of Juno Therapeutics in a research report on Tuesday, June 6th. Finally, BidaskClub cut shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, June 10th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $34.88.
The company’s market cap is $4.68 billion. The stock’s 50 day moving average is $33.60 and its 200-day moving average is $26.98.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. During the same period in the prior year, the company posted ($0.64) earnings per share. The firm’s revenue was down 22.8% compared to the same quarter last year. Equities analysts predict that Juno Therapeutics, Inc. will post ($3.12) EPS for the current fiscal year.
In other news, CFO Steve Harr sold 8,750 shares of the stock in a transaction that occurred on Tuesday, June 27th. The stock was sold at an average price of $30.00, for a total value of $262,500.00. Following the completion of the sale, the chief financial officer now directly owns 736,189 shares of the company’s stock, valued at $22,085,670. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $27.00, for a total value of $216,000,000.00. The disclosure for this sale can be found here. Insiders sold 8,119,219 shares of company stock valued at $220,455,844 over the last three months. 15.26% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of JUNO. The Manufacturers Life Insurance Company boosted its position in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the period. Pacad Investment Ltd. bought a new position in Juno Therapeutics in the second quarter worth $105,000. QS Investors LLC bought a new position in Juno Therapeutics in the second quarter worth $135,000. Great West Life Assurance Co. Can lifted its position in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 3,800 shares during the period. Finally, Nisa Investment Advisors LLC bought a new position in Juno Therapeutics in the first quarter worth $200,000. 70.76% of the stock is owned by institutional investors.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.